unknown
Stage
2018
Founded
2
Investors
About
Delfi Diagnostics develops AI-driven liquid biopsy tests that analyze cell-free DNA fragmentation patterns from blood samples to detect lung cancer early and monitor treatment.
Explore Delfi Diagnostics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.